507
On 7th of November 2005 a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number EU/3/05/329. The active ingredient is Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN) for treatment of localised scleroderma..